Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct 1;49(10):975-977.
doi: 10.1097/RLU.0000000000005251. Epub 2024 May 20.

Myelodysplastic Syndrome Related to Successful Treatment With 177 Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer

Lavinia Vija Racaru, Mehdi Krim  1 , Valérian Rivet  2 , Loic Mourey  1 , Pr Frederic Courbon
Affiliations
Case Reports

Myelodysplastic Syndrome Related to Successful Treatment With 177 Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer

Lavinia Vija Racaru et al. Clin Nucl Med. .

Abstract

177 Lu-vipivotide tetraxetan ( 177 Lu-PSMA-617/LuPSMA) received recent EMA approval for metastatic castration-resistant prostate cancer, with promising data for earlier stages. Secondary myeloid neoplasm following exposure to DNA-damaging therapy (therapy-related myelodysplastic syndrome [MDS]) is a rare severe complication of 177 Lu-oxodotreotide. We present a 77-year-old man, with synchronous liver, bone, and lymph node metastatic prostate cancer, having developed a low-risk MDS with SF3B1 mutation, 1 month after the sixth administration of LuPSMA. Although on partial metabolic and biological response with PSA nadir at 7 months after therapy, life quality was significantly altered by MDS.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

References

    1. Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol . 2023;83:405–412.
    1. Loghavi S, Kanagal-Shamana R, Khoury JD, et al. Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms. Mod Pathol . 2024;37:100397.
    1. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood . 2012;120:2454–2465.
    1. Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematol Am Soc Hematol Educ Program . 2020;2020:426–433.
    1. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med . 2020;382:140–151.

Publication types

MeSH terms